FXYD5 antibody - middle region (ARP35226_T100)
- Known as:
- FXYD5 (anti-) - middle region (ARP35226_T100)
- Catalog number:
- arp35226_t100
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- FXYD5 antibody - middle region (ARP35226_T100)
Related genes to: FXYD5 antibody - middle region (ARP35226_T100)
- Gene:
- FXYD5 NIH gene
- Name:
- FXYD domain containing ion transport regulator 5
- Previous symbol:
- -
- Synonyms:
- OIT2
- Chromosome:
- 19q13.12
- Locus Type:
- gene with protein product
- Date approved:
- 2000-05-23
- Date modifiied:
- 2014-11-19
Related products to: FXYD5 antibody - middle region (ARP35226_T100)
Related articles to: FXYD5 antibody - middle region (ARP35226_T100)
- Erythro-myeloid progenitors (EMPs) originate from the haemogenic endothelium in the yolk sac via an endothelial-to-haematopoietic transition (EHT) to generate blood and immune cells that support embryo development. Yet, the transitory nature of EHT and the limited availability of molecular markers have constrained our understanding of the origin, identity, and differentiation dynamics of EMPs. Here, we have refined the annotation of yolk sac haemato-vascular populations in publicly available single-cell RNA sequencing (scRNAseq) datasets from mouse embryos to identify novel molecular markers of haemogenic endothelium and EMPs. By sub-clustering key cell populations followed by pseudotime analysis, we refined cluster annotations and then reconstructed differentiation trajectories. Subsequent differential gene expression analysis between clusters identified novel cell surface markers for haemogenic endothelial cells ( and ) and EMPs (, and ). Further, we have identified candidate signalling and metabolic pathways that may regulate yolk sac haematopoietic emergence and differentiation. The specificity of FXYD5, SCARF1, and FCER1G for haemogenic endothelium and EMPs was validated by immunostaining of the mouse yolk sac. These insights into the transcriptional dynamics in the yolk sac should support future investigation of EHT and haematopoietic differentiation during early mammalian development. - Source: PubMed
Publication date: 2026/01/06
Diez-Pinel GuillermoMuratore AlessandroRuhrberg ChristianaCanu Giovanni - Gastric cancer (GC) remains a major global health challenge, characterized by high morbidity and mortality rates. Early diagnosis is essential for improving patient outcome. This study aims to develop a diagnostic model based on specific signature genes by investigating the association between double-negative (DN) T cells and GC. - Source: PubMed
Publication date: 2026/01/12
Yin ZhijingZhang GanghuaYin ZiweiMa WeinaYang JingxinDeng WenzhiFeng ZiyangWang ZhanwangJin YiZhu YuxingCao Ke - Pancreatic cancer (PC) is a highly malignant and aggressive gastrointestinal malignancy with a poor prognosis for patients. Aerobic glycolysis serves as a critical metabolic driver of PC progression. Our study aims to elucidate the mechanism by which FXYD5 regulates aerobic glycolysis in PC. - Source: PubMed
Publication date: 2025/09/17
Xie HongminLiao LangxiaLi JiaxuanCai RunshengHe HongBiaoLu Min - Glioblastoma (GBM) is an extremely aggressive brain tumor, marked by restricted therapeutic possibilities and a generally unfavorable prognosis. GBM's complexity and heterogeneity necessitate comprehensive genetic and immunological profiling to enhance therapeutic strategies. - Source: PubMed
Zhang LulinChen WeiHuang WeibinCheng Haoling - Myocardial ischemia/reperfusion (I/R) injury is a common cause of death. FXYD domain-containing ion transport regulator-5 (Fxyd5) is a type I membrane protein that plays a significant role in mediating cellular functions. However, the expression and function of Fxyd5 in myocardial I/R injury remain unclear. - Source: PubMed
Publication date: 2025/09/03
Zhang LeiXu JunjieCui FujiangJin JinLiu LiwenWang LeiGao Yuxia